<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: We initiated this preclinical study in order to analyze the impact of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> single treatment versus combination treatment in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The effect of increasing <z:chebi fb="0" ids="50924">sorafenib</z:chebi> doses on proliferation, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, migration, and activation of signal cascades was analyzed in vitro </plain></SENT>
<SENT sid="2" pm="."><plain>The effect of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> single treatment versus <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) single treatment and combination therapy on in vivo proliferation and target cytokine receptor/ligand expression was analyzed in a human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> xenograft mouse model using HT29 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: In vitro, SW480 and HT29 cell lines were sensitive to <z:chebi fb="0" ids="50924">sorafenib</z:chebi>, as compared to Caco2 and SW620 cell lines, independent of the mutation status of K-ras, Raf, PTEN, or PI3K </plain></SENT>
<SENT sid="4" pm="."><plain>The effect on migration was marginal, but distinct differences in caspases activation were seen </plain></SENT>
<SENT sid="5" pm="."><plain>Combination strategies were beneficial in some settings (<z:chebi fb="0" ids="50924">sorafenib</z:chebi> + 5-FU; irinotecan) and disadvantageous in others (<z:chebi fb="0" ids="50924">sorafenib</z:chebi> + <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>), depending on the chemotherapeutic drug and cell line chosen </plain></SENT>
<SENT sid="6" pm="."><plain>Sensitive cell lines revealed a downregulation of AKT and had a weak expression level of GADD45β </plain></SENT>
<SENT sid="7" pm="."><plain>In resistant cell lines, pp53 and GADD45β levels decreased upon <z:chebi fb="0" ids="50924">sorafenib</z:chebi> exposure </plain></SENT>
<SENT sid="8" pm="."><plain>In vivo, the combination treatment of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> and 5-FU was equally effective as the respective monotherapy concerning <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> proliferation </plain></SENT>
<SENT sid="9" pm="."><plain>Interestingly, treatment with either <z:chebi fb="0" ids="50924">sorafenib</z:chebi> or 5-FU resulted in a significant decrease of VEGFR1 and PDGFRβ expression intensity </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, a sensitivity towards <z:chebi fb="0" ids="50924">sorafenib</z:chebi> exists, which seems similarly effective as a 5-FU monotherapy </plain></SENT>
<SENT sid="11" pm="."><plain>A combination therapy, in contrast, does not show any additional effect </plain></SENT>
</text></document>